Nuo Therapeutics (AURX) CEO/CFO nets 99,619 shares in option exercise

Rhea-AI Filing Summary

Nuo Therapeutics CEO/CFO and director David Jorden reported an insider stock option exercise. On 01/01/2026, he exercised an option to purchase 125,000 shares of Nuo Therapeutics, Inc. common stock at an exercise price of $0.40 per share using a net exercise method.

The company withheld 25,381 shares, valued at the closing price of $1.97 per share, to cover the exercise cost, and Jorden received 99,619 shares of common stock. Following these transactions, he directly beneficially owned 2,046,374 shares of Nuo Therapeutics common stock, and the reported option position was reduced to zero.

Insider Trade Summary

125,000 shares exercised/converted

Mixed 3 txns

Insider JORDEN DAVID EMERSON

Role CEO/CFO

Type	Security	Shares	Price	Value
Exercise	Common Stock	125,000	$0.40	$50K
Tax Withholding	Common Stock	25,381	$1.97	$50K
Exercise	Option to purchase common stock	125,000	$0.00	--

Holdings After Transaction: Common Stock — 2,071,755 shares (Direct); Option to purchase common stock — 0 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

JORDEN DAVID EMERSON

(Last) (First) (Middle)

C/O NUO THERAPEUTICS, INC.

8285 EL RIO, SUITE190

(Street)

HOUSTON TX 77054

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Nuo Therapeutics, Inc. [ AURX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CEO/CFO

3. Date of Earliest Transaction (Month/Day/Year)
01/01/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/01/2026		M		125,000	A	$0.4	2,071,755	D
Common Stock	01/01/2026		F(1)		25,381	D	$1.97	2,046,374	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Option to purchase common stock	$0.4	12/31/2018		M			125,000	12/31/2018	01/01/2026	Common Stock	125,000	$0	0	D

Explanation of Responses:

1. Represents a net exercise of outstanding stock options. The reporting person received 99,619 shares of common stock on the net exercise of option to purchase 125,000 shares of common stock. The issuer withheld 25,381 shares of common stock underlying the option for payment of the exercise price using the closing price of $1.97.

	/s/ David Jorden	01/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Nuo Therapeutics (AURX) report in this Form 4?

The filing reports that David Jorden, CEO/CFO and a director of Nuo Therapeutics, Inc., exercised a stock option for 125,000 shares of common stock on 01/01/2026 using a net exercise.

How many Nuo Therapeutics (AURX) shares did the insider actually receive?

On the net exercise, the reporting person received 99,619 shares of Nuo Therapeutics common stock. The issuer withheld 25,381 shares to pay the exercise price.

What prices were used in the Nuo Therapeutics (AURX) insider option exercise?

The option had an exercise price of $0.40 per share. To cover the cost, the issuer withheld shares using the common stock closing price of $1.97 per share.

How many Nuo Therapeutics (AURX) shares does the insider own after this transaction?

After the reported transactions, the filing states that the reporting person beneficially owned 2,046,374 shares of Nuo Therapeutics common stock in direct ownership form.

What happened to the stock option reported by Nuo Therapeutics (AURX) in this Form 4?

The option to purchase Nuo Therapeutics common stock at $0.40 per share for 125,000 shares was exercised on 01/01/2026, and the number of derivative securities beneficially owned after the transaction is reported as 0.

What roles does the reporting person hold at Nuo Therapeutics (AURX)?

The reporting person is identified as both a Director and an Officer of Nuo Therapeutics, serving as CEO/CFO.